EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische Studie

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma

Yael C Cohen, Hila Magen, Moshe Gatt, Michael Sebag, Kihyun Kim, Chang-Ki Min, Enrique M Ocio, Sung-Soo Yoon, Michael P Chu, Paula Rodríguez-Otero, Irit Avivi, Natalia A Quijano Cardé und 12 weitere

New England Journal of Medicine · 09.01.2025 · 392 (2) · 138-149

DOI: 10.1056/nejmoa2406536 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 09.01.2025. Verfasst von Yael C Cohen und 23 weiteren Autor:innen. Beteiligte Einrichtung: From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel A…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antineoplastic Combined Chemotherapy Protocols, B-Cell Maturation Antigen, Multiple Myeloma. Die Arbeit wurde bisher 128-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntineoplastic Combined Chemotherapy ProtocolsB-Cell Maturation AntigenMultiple MyelomaReceptors, G-Protein-CoupledNeoplasm Recurrence, LocalAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDose-Response Relationship, DrugMaximum Tolerated DoseRecurrenceDrug Resistance, NeoplasmTreatment Outcome

Substanzen

Antibodies, BispecificB-Cell Maturation AntigenGPRC5D protein, humanReceptors, G-Protein-Coupled

Autor:innen und Institutionen

  • From Tel Aviv Sourasky Medical Center (Y.C.C., I.A.), and the Faculty of Medical and Health Sciences, Tel Aviv University (Y.C.C., H.M., I.A.), Tel Aviv, Chaim Sheba Medical Center, Ramat Gan (H.M.), and Hadassah Hebrew…

Förderung

  • Janssen Research and Development

Zitieren

APA

Cohen, Y. C., Magen, H., Gatt, M., Sebag, M., Kim, K., Min, C. K., Ocio, E. M., Yoon, S. S., Chu, M. P., Rodríguez-Otero, P., Avivi, I., Quijano Cardé, N. A., Kumar, A., Krevvata, M., Peterson, M. R., Di Scala, L., Scott, E., Hilder, B., Vanak, J., …, & RedirecTT-1 Investigators and Study Group (2025). Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 392(2), 138-149. https://doi.org/10.1056/nejmoa2406536

Vancouver

Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, et al. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 2025;392(2):138-149. doi:10.1056/nejmoa2406536

BibTeX
@article{Cohen2025,
  author = {Cohen, Yael C and Magen, Hila and Gatt, Moshe and Sebag, Michael and Kim, Kihyun and Min, Chang-Ki and Ocio, Enrique M and Yoon, Sung-Soo and Chu, Michael P and Rodríguez-Otero, Paula and Avivi, Irit and Quijano Cardé, Natalia A and Kumar, Ashwini and Krevvata, Maria and Peterson, Michelle R and Di Scala, Lilla and Scott, Emma and Hilder, Brandi and Vanak, Jill and Banerjee, Arnob and Oriol, Albert and Morillo, Daniel and Mateos, María-Victoria and RedirecTT-1 Investigators and Study Group, RedirecTT-1 Investigators and Study Group},
  title = {Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {2},
  pages = {138--149},
  doi = {10.1056/nejmoa2406536}
}
Kostenlos starten →